Dr. Kunwar Shailubhai, CEO, Tiziana Life Sciences 00:00:00
Tiziana Life Sciences PLC's CEO Dr. Kunwar Shailubhai tells Proactive a second patient with Secondary Progressive Multiple Sclerosis (SPMS) in an ongoing study has shown clinical improvements following three months of treatment with its intranasal drug foralumab.